Metrics as of 10/15/2026, 08:34 AM (Berlin time), refresh in progress.
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Catherine E. Owen Adams
- Employees
- 797
- Market cap
- $3.3 B
- IPO
- 27/05/2004
Acadia Pharmaceuticals Inc. is a biopharmaceutical company operating within the Healthcare sector and the Biotechnology industry. Headquartered in San Diego, USA, the company focuses primarily on the discovery, development, and commercialization of small molecule therapeutics. Its core mission involves addressing…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Acadia Pharmaceuticals stock: price history
1D
-3.0%
1W
-3.3%
1M
-30.6%
6M
-13.8%
YTD
-28.4%
1Y
-7.3%
2Y
+27.1%
5Y
+9.2%
10Y
-21.4%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~25% weaker price swings than usual
Acadia Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Acadia Pharmaceuticals Inc. is a specialized biopharmaceutical company focused on developing and marketing therapeutics for central nervous system disorders. The company's core product is Nuplazid, which is used to treat hallucinations and delusions associated with Parkinson's psychosis. In addition to this established medication, the company maintains a broad research pipeline with various drug candidates in clinical development stages. These target indications such as Alzheimer's dementia, Rett syndrome, and various forms of acute and chronic pain. The business model is primarily characterized by the sale of pharmaceutical products and requires substantial investments in the development of new drug candidates due to intensive research requirements.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Acadia Pharmaceuticals
Analyst assessment of Acadia Pharmaceuticals
PRICE TARGET LOW
US$14.50
CONSENSUS
US$29.95
MEDIAN
US$33.00
PRICE TARGET HIGH
US$37.00
0
STRONG BUY
25
BUY
11
HOLD
1
SELL
0
STRONG SELL
37
TOTAL · Buy
As of: 13/10/2026
Acadia Pharmaceuticals stock metrics
P/E
8.5
P/B
2.51
EV/EBITDA
25.71
RETURN ON EQUITY
2.4%
NET MARGIN
10.2%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.8%
FLOAT SHARES
170,043,105
AVG. DAILY VOLUME (30D)
2,159,031
Insider transactions (SEC)
Schneyer Mark C.
Schneyer Mark C.
Schneyer Mark C.
Schneyer Mark C.
Schneyer Mark C.
Institutional holders
Comparable stocks
Frequently asked questions about Acadia Pharmaceuticals stock
What does Acadia Pharmaceuticals do?
Acadia Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Catherine E. Owen Adams, the company employs around 797 people.
The IPO was on 27/05/2004; the stock trades on NASDAQ under the ticker ACAD.
What do analysts say about Acadia Pharmaceuticals stock?
37 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$29.95, ranging from US$14.50 to US$37.00, with a median of US$33.00.
This is an external assessment, not a statement by Market Jury.
When does Acadia Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -25% stronger than usual.
Does Acadia Pharmaceuticals pay a dividend?
No, Acadia Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Acadia Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Acadia Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Acadia Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.